Targeted liposomal drug delivery systems for the treatment of B cell malignancies

Abstract

Nanoparticulate systems have demonstrated significant potential for overcoming the limitations of non-specific adverse effects related to chemotherapy. The treatment of blood malignancies employing targeted particulate drug delivery systems presents unique challenges and considerable research has been focused towards the development of targeted liposomal formulations for B cell malignancies. These formulations are aimed at achieving selectivity towards the malignant cells by targeting several cell surface markers which are over-expressed in that specific malignancy. CD19, CD20, CD22 and CD74 are few of such markers of which CD19, CD22 and CD74 are internalizing and CD20 is non-internalizing. Systems which have been developed to target both types of these cell surface markers are discussed. Specifically, the efficacy and development of targeted liposomes is considered. A number of studies have demonstrated the advantages of targeted liposomal systems encapsulating doxorubicin or vincristine. However, liposomal encapsulation of newer anti-neoplastic agents such as AD 198 which are superior to doxorubicin should be considered.

Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier

“…For example liposomal encapsulation of antineoplastic agents such as AD 198 has been made that is proved to be superior to doxorubicin [261]. Similarly, PEG-coated irinotecan cationic liposomes have shown better therapeutic efficacy against breast cancer in animals [262]. Furthermore, many improved liposomal formulations such as loaded ethosomes to carry drugs across human skin [263], terbinafine HCL liposomes for cutaneous delivery [264], and curcumin-loaded cationic liposomes are prepared for various cancer therapies [265].…”

Formulation, Development, and In Vitro Evaluation of a CD22 Targeted Liposomal System Containing a Non-Cardiotoxic Anthracycline for B Cell Malignancies

“…The treatment of hematological malignancies presents considerable differences from solid cancers in that a large population of the cancer cells are circulating. In a previous review [ 25 ] we had discussed the potential of nanoparticles, such as targeted liposomes, being utilized for targeted therapies for B cell cancers. Drug delivery scientists have worked towards the development of a targeted nanoparticulate system for the treatment of B cell cancers [ 11 , 13 , 14 , 23 , 26 , 27 , 28 , 29 , 30 , 31 ].…”

Review peptide‐targeted liposomes for selective drug delivery: Advantages and problematic issues

“…In order to accumulate the drug only on target organs and inside malignant cells new delivery systems based on micelles or liposomes externally modified with bioactive ligands, such as peptides . or antibodies, have been recently proposed. For example, target‐selective theranostic agents have been developed either by adding a peptide on the external surface of liposomes to obtain target selective liposomal drugs or by including a probe in the final composition.…”